APA (7th ed.) Citation

Hänse, N., & Marmé, F. (2016). A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BioMed Central; Springer. https://doi.org/10.1186/s12885-016-2449-0

Chicago Style (17th ed.) Citation

Hänse, Nicole, and Frederik Marmé. A Phase I Trial of the Trifunctional Anti Her2 × Anti CD3 Antibody Ertumaxomab in Patients with Advanced Solid Tumors. London; Berlin; Heidelberg: BioMed Central; Springer, 2016. https://doi.org/10.1186/s12885-016-2449-0.

MLA (9th ed.) Citation

Hänse, Nicole, and Frederik Marmé. A Phase I Trial of the Trifunctional Anti Her2 × Anti CD3 Antibody Ertumaxomab in Patients with Advanced Solid Tumors. BioMed Central; Springer, 2016. https://doi.org/10.1186/s12885-016-2449-0.